Three-Day Treatment For Bacterial Vaginosis Gets FDA Approval
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Three-Day Treatment For Bacterial Vaginosis Gets FDA Approval

LONDON, ENGLAND -- March 3, 1998 -- The United States Food and Drug Administration has approved Pharmacia & Upjohn’s three-day treatment option for Cleocin Vaginal Cream 2% (clindamycin phosphate) for the treatment of bacterial vaginosis (BV) in non-pregnant women.

Cleocin Vaginal Cream is now the only three-day treatment option available to non-pregnant women with BV. The prescription-only product will be available in pharmacies by April 1998.

The product was first marketed in the U.S. in 1992, as a seven-day course of therapy. Along with approval of the three-day therapy option, the FDA has also added pregnant women in their third trimester to the population who can be treated with the seven-day treatment option. The three-day treatment option is not recommended for pregnant women with BV. The seven-day treatment option may be used by both pregnant and non-pregnant patients.

Bacterial vaginosis is the most common type of vaginal infection in women of reproductive age and accounts for one-third of all vaginal infections. The symptoms include a white vaginal discharge accompanied by an unpleasant odour. The presence of BV can only be diagnosed by a health care professional during a physical examination.

Available only by prescription, Cleocin Vaginal Cream three-day treatment option comes in a new 21-gram tube with three disposable applicators. The recommended dose for non-pregnant women is one full applicator inserted intravaginally, at bedtime, for three or seven consecutive days. The existing 40-gram tube with seven disposable applicators will still be available for patients receiving prescriptions for seven-day treatment.

Cleocin Vaginal Cream is not recommended for individuals with a history of hypersensitivity to clindamycin, lincomycin or any of the components of the vaginal cream. It should not be used in individuals with a history of regional enteritis, ulcerative colitis or a history of antibiotic-associated colitis. The most common side effects are vaginitis and candida albicans vaginal infections.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities